NEW YORK/LONDON (Reuters) -U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping ...

By Mariam Sunny (Reuters) -Shares of Metsera fell over 15% in early trading on Monday, after the weight-loss drug developer ...

The US drug giant beat Novo Nordisk in the $10 bln battle for biotech Metsera with the help of the Federal Trade Commission.

Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war ...

The announcement of the deal signaled an end to the bidding war for Metsera between Pfizer and Novo Nordisk, the Danish maker ...

Nov 5 (Reuters) - Pfizer (PFE.N) plans to sweeten its bid for Metsera (MTSR.O), a person familiar with the matter told ...

Pfizer’s third quarter results reflected ongoing challenges in its COVID-19 franchise, but management pointed to solid growth ...

The bidding war between Pfizer ( PFE) and Novo Nordisk ( NVO) over obesity drug developer Metsera ( MTSR) finally ended over ...

Pfizer is preparing to sweeten its offer again for Metsera, the weight-loss drug startup at the center of a bidding war that ...

“No need for a reunion show: This seasons Real Housewives of Biopharma comes to a close with Pfizer’s winning bid for Metsera ...

Pfizer Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma ...

Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, ...